ALBO - Albireo gets reimbursed access to liver disease drug Bylvay in Italy
- Albireo Pharma ( NASDAQ: ALBO ) said the Italian Medicines Agency has enabled reimbursed access to Bylvay (odevixibat) to treat all types of patients with progressive familial intrahepatic cholestasis (PFIC) in Italy.
- PFIC is a rare progressive, liver disease.
- Bylvay was granted Full Therapeutic Innovation status by Agenzia Italiana del Farmaco (AIFA), a designation for some products with unmet need and added clinical benefit, Albireo said in a Sept. 6 press release.
For further details see:
Albireo gets reimbursed access to liver disease drug Bylvay in Italy